England’s Innovative Medicines Fund: Opportunities & Risks
Executive Summary
England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.
You may also be interested in...
England Launches Innovative Medicines Fund
The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.